1292211-22-3

Upstream product

• 1292211-21-2 ethyl 2-((8-(benzyloxy)-5-(6-(tert-butoxycarbonylamino)hexylamino)-1,6-naphthyridine-7-carboxamido)methyl)-5-fluorobenzoate 
• 100-39-0 benzyl bromide 
• 410544-37-5 5-bromo-8-hydroxy-[1,6]naphthyridine-7-carboxylic acid methyl ester 
• 1292211-19-8 methyl 8-(benzyloxy)-5-(6-(tert-butoxycarbonylamino)hexylamino)-1,6-naphthyridine-7-carboxylate 
• 1292211-20-1 8-(benzyloxy)-5-(6-(tert-butoxycarbonylamino)hexylamino)-1,6-naphthyridine-7-carboxylic acid 
• 1292211-00-7 methyl 8-(benzyloxy)-5-bromo-1,6-naphthyridine-7-carboxylate 

Downstream Products

• 1292211-24-5 2-((5-(6-aminohexylamino)-8-(benzyloxy)-1,6-naphthyridine-7-carboxamido)methyl)-5-fluorobenzoic acid trifluoroacetate 
• 1292211-25-6 C₃₀H₃₀FN₅O₃ 

Relevant academic research and scientific papers

Macrocyclic integrase inhibitors for use in the treatment of feline immunodeficiency virus

This invention concerns to naphthyridin derivatives of formula (I) for use in the treatment or prevention of feline immunodeficiency virus (FIV). Furthermore the present invention relates to a method of treating or preventing infection of feline immunodeficiency virus in a feline animal wherein said method comprises the administration to said feline animal of a therapeutically effective amount of a naphthyridin derivative.

MACROCYCLIC INTEGRASE INHIBITORS FOR USE IN THE TREATMENT OF FELINE IMMUNODEFICIENCY VIRUS

This invention concerns to naphthyridin derivatives of formula (I) for use in the treatment or prevention of feline immunodeficiency virus (FIV). Furthermore the present invention relates to a method of treating or preventing infection of feline immunodeficiency virus in a feline animal wherein said method comprises the administration to said feline animal of a therapeutically effective amount of a naphthyridin derivative.

MACROCYCLIC INTEGRASE INHIBITORS

Compound having formula (I), wherein - W is NH-, -N(CH3)- or piperazine, - X is a bond, -C(=O)- or S(=O)2-, - Y is C3-7alkylene, and - Z is NH-C(=O)- or -O-, and pharmaceutically acceptable salts thereof, their pharmaceutical formulations and use as HIV inhibitors.